Allakos Inc

Allakos — Corporate Update (August 2019)

41 slides from Allakos's corporate update, Aug 5, 2019

  1. Slide 1: Phase 2 Eosinophil Gastritis and Gastroenteritis Study Results

    Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Phase 2 Eosinophil Gastritis and Gastroenteritis Study Results Aug 5, 2019 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b

  3. Slide 3: Agenda

    Agenda Robert Alexander, PhD Overview 5:00 – 5:15 AM Henrik Rasmussen, MD PhD Results of the ENIGMA Phase 2 Study 5:15 – 5:45 AM Evan Dellon, MD MPH Physician Perspective 5:45 – 5:55 AM Q&A 5:55 AM

  4. Slide 4: Overview

    Overview Robert Alexander, PhD CEO – Allakos

  5. Slide 5: Executive Summary

    Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom

  6. Slide 6: Mast Cells and Eosinophils: Effector Cells Central to Inflammatory Responses

    Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines

  7. Slide 7: AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils

    AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response AK002 Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis AK002

  8. Slide 8: Mast Cells and Eosinophils are Key Drivers of Inflammatory Disease

    Mast Cells and Eosinophils are Key Drivers of Inflammatory Disease T Cell B Cell Activated B Cell Mast Cell IgE Activation and Recruitment of Other Immune Cells and Tissue Inflammation Macrophage Eosinophil Neutrophil Allergens Smooth Muscle Neuron Epithelium ACUTE AND CHRONIC INFLAMMATION SENSITIZA

  9. Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases

    Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Gastroenteritis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTES

  10. Slide 10: Eosinophilic Gastrointestinal Diseases (EGIDs)

    Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM/ SMALL INTESTINE Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Gastroenteritis (EGE) = US Prevalence ~20-25K ~25K ~200K EG, EGE, EoE Chronic Eosinophilic Inflammation of the Stomach, Small Intestine,

  11. Slide 11: Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2 Study

    Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2 Study Henrik S. Rasmussen, MD PhD Chief Medical Officer - Allakos

  12. Slide 12: ENIGMA Phase 2 Study Design

    ENIGMA Phase 2 Study Study Design Randomized, double-blind, placebo-controlled study in EG/EGE Active moderate to severe symptoms Biopsy confirmed EG/EGE Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 65 Patients – 3 arms 22 patients 0.3, 1.0, 1.0, 1.0 mg/kg 21 p

  13. Slide 13: Symptoms Assessed Using Proprietary PRO

    Symptoms Assessed Using Proprietary PRO Abdominal pain Nausea Vomiting Early satiety Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the symptoms of EG/EGE patients on a daily basis Measures 8 symptoms each on a scale of 0-1

  14. Slide 14: Prespecified Hierarchical Analysis Per Protocol

    Prespecified Hierarchical Analysis Per Protocol Primary Endpoint Mean percent change in gastrointestinal eosinophil counts from baseline Responder Secondary Endpoint Proportion of patients who have: >75% decrease in tissue eosinophils AND >30% benefit in Total Symptom Score (TSS) Symptoms Secondary

  15. Slide 15: Baseline Characteristics

    Baseline Characteristics AK002 (n=39) Placebo (n=20) Total (N=59) Age, Median (Range) 43 (18-74) 40 (18-67) 42 (18-74) Female 72% 50% 64% EoE with Dysphagia 38% (15) 50% (10) 42% (25) % of Patients with AEC1 <500 eos/µL 74% 60% 69% % of Patients with AEC1 <1500 eos/µL 95% 95% 95% Mean Baseline Gastr

  16. Slide 16: Primary Endpoint Met for All AK002 Groups

    Primary Endpoint Met for All AK002 Groups Treatment Arm Baseline Eosinophil Counts / hpf Mean %∆ in Eosinophil Counts p - value High Dose AK002 (n=20) 76 -97% <0.0001 Low Dose AK002 (n=19) 80 -92% <0.0001 Combined AK002 (n=39) 78 -95% <0.0001 Placebo (n=20) 75 +10% -

  17. Slide 17: AK002 Demonstrates Potent Tissue Eosinophil Depletion

    37 of 39 patients had < 5 eos/hpf Stomach/Duodenal Eos < 5/HPF AK002 Demonstrates Potent Tissue Eosinophil Depletion % of Patients AK002 Placebo (0/20) (37/39)

  18. Slide 18: AK002 Met Patient Reported Symptoms Secondary Endpoint

    AK002 Met Patient Reported Symptoms Secondary Endpoint Statistically significant improvements in symptoms observed 1 day after first infusion and maintained throughout the study Treatment Arm Baseline TSS Mean % Change in TSS p - value High Dose AK002 (n=20) 34 -58% 0.0012 Low Dose AK002 (n=19) 35 -

  19. Slide 19: Higher Proportion of Patients with >50% Reduction in TSS on AK002 vs. Placebo

    Higher Proportion of Patients with >50% Reduction in TSS on AK002 vs. Placebo Confidential % of Patients Placebo High Dose High/Low Low Dose AK002 EG/EGE-PRO Total Symptom Score: >50% Reduction (3/20) (13/20) (25/39) (12/19)

  20. Slide 20: Improvement Across All Symptoms Measured on AK002

    Improvement Across All Symptoms Measured on AK002 Confidential EG/EGE-PRO Symptom Score AK002 (n=39) Median Score -59% -79% -100% -65% -61% -57% -47% -55% Baseline End of Tx

  21. Slide 21: AK002 Met Treatment Responder Secondary Endpoint

    AK002 Met Treatment Responder Secondary Endpoint Treatment Arm Treatment Responders p - value High Dose AK002 (n=20) 70% 0.0009 Low Dose AK002 (n=19) 68% 0.0019 Combined AK002 (n=39) 69% 0.0008 Placebo (n=20) 5% - Treatment responder defined as: >75% reduction in tissue eosinophil counts AND >30% re

  22. Slide 22: Additional Analyses

    Additional Analyses

  23. Slide 23: Endpoint Sensitivity Analyses

    Endpoint Sensitivity Analyses Intent to Treat (ITT): All patients randomized (n=65) Includes Per Protocol (n=59) population plus: 2 patients only received 1 dose of drug 1 patient did not complete PRO 3 patients had their daily steroid dose altered Safety evaluated on the ITT population Protocol all

  24. Slide 24: All Analyses Show Consistent Results

    All Analyses Show Consistent Results Primary and Secondary Endpoint p-values AK002 Dose Groups Placebo High (n=20/16/21) Low (n=19/12/22) High/Low (n=39/28/43) (n=20/13/22) 1° - Tissue Eosinophils % Δ from BL to Day 99 Per Protocol <0.0001 <0.0001 <0.0001 - No Steroids <0.0001 <0.0001 <0.0001 - ITT

  25. Slide 25: Eosinophilic Esophagitis Patients

    Eosinophilic Esophagitis Patients AK002 (n=15) Placebo (n=10) Total (N=25) Age, Median (Range) 34 (18-68) 34 (21-53) 34 (18-68) Female 67% 40% 56% Mean Baseline Esophageal Eosinophils/hpf 43 79 56 Mean Baseline Esophageal Mast Cells/hpf 28 36 31 Mean Baseline Dysphagia Score 4.0 4.4 4.2

  26. Slide 26: Significant Eosinophil Reductions in Patients With EoE

    Esophageal Eos < 5/HPF1 Significant Eosinophil Reductions in Patients With EoE % of Patients AK002 Placebo *p <0.0001 * 13 of 14 patients had < 5 eos/hpf (1/9) (13/14) 1Excludes patients with eos < 5/hpf at baseline

  27. Slide 27: Substantial Improvement in Dysphagia

    Severity of Dysphagia1 Substantial Improvement in Dysphagia Histological and symptomatic improvement provides strong proof of concept in EoE 1All EoE patients with end of treatment dysphagia scores Mean %∆ from BL AK002 (n=12) Placebo (n=8)

  28. Slide 28: Mast Cell Counts Decrease on AK002

    Mast Cell Counts Decrease on AK002 Mast Cells in Gastric, Duodenal, and Esophageal Biopsies Baseline Day 99 Mean Peak Cell Count / hpf -17% -26%* -20% -3% +1% -9% *p <0.05 n= 39 39 BL=22, Day 99 = 21 20 20 BL=12, Day 99 = 10 AK002 Placebo

  29. Slide 29: Safety Summary

    Safety Summary

  30. Slide 30: Safety: Treatment-Emergent AEs in ≥5% of Patients

    Safety: Treatment-Emergent AEs in ≥5% of Patients % of Patients, (n) AK002 (n=43) Placebo (n=22) Infusion related reaction 60% (26) 23% (5) Headache 9% (4) 9% (2) Upper respiratory tract infection 9% (4) 9% (2) Urinary tract infection 9% (4) 5% (1) Nausea 7% (3) 14% (3) Fatigue 7% (3) 9% (2) Diarrhe

  31. Slide 31: Safety Summary

    Safety Summary Generally well tolerated Most common AE was mild to moderate infusion related reactions (IRR) 60% of AK002 patients vs 23% placebo 93% mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness) Mostly on first infusion, greatly reduced or does not occur on subsequent

  32. Slide 32: Open-Label Extension & Next Steps

    Open-Label Extension & Next Steps

  33. Slide 33: Extension Study Status

    Extension Study Status 92% of patients elected to enter long-term extension study Current median duration of treatment 3 months Efficacy appears to improve with continued dosing Optimizing dose administration Pre-dose with oral prednisone 1 day prior to first and second AK002 doses No IRRs observed

  34. Slide 34: EG/EGE and EoE Next Steps

    EG/EGE and EoE Next Steps Q4 2019/Q1 2020 End of phase 2 meeting Q1 2020 Estimated phase 3 study start eosinophilic gastritis and/or eosinophilic gastroenteritis Q1 2020 Estimated phase 2/3 study start in eosinophilic esophagitis

  35. Slide 35: Evan S. Dellon, MD MPH

    Evan S. Dellon, MD MPH TITLE:Professor of Medicine, Gastroenterology & Epidemiology Director, Center for Esophageal Diseases and Swallowing Director, CGIBD Biostatistics and Clinical Research Core INSTITUTION:University of North Carolina School of Medicine SPECIALTY:Gastroenterology FOCUS:Epidemiolo

  36. Slide 36: Corporate Updates

    Corporate Updates

  37. Slide 37: Strong Balance Sheet and Significant IP Protection

    Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of June 30, 2019 $153.1M Q2 2019 Operating Expenses $20.1M AK002 US patents run until 2035 Lonza currently manufactures AK002

  38. Slide 38: Anticipated Near-term Milestones

    Anticipated Near-term Milestones Q1’20 Phase 3 EG/EGE and EoE Study starts H2’20 Phase 1 Data For subcutaneous AK002 Q4’19/Q1’20 End of Phase 2 Meeting Q1’20 Phase 1 Data in Mast Cell GI H1’20 Phase 2 Extension Data in EG and/or EGE

  39. Slide 39: Experienced Management Team

    Experienced Management Team Previous Experience Robert Alexander, PhD Chief Executive Officer CEO, ZS Pharma Director Alta Partners; Business Development, Genentech Adam Tomasi, PhD President & COO CSO & Head of Corporate Development, ZS Pharma Principal Alta Partners, Drug Discovery, Gilead, Cytoki

  40. Slide 40: Executive Summary

    Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom

  41. Slide 41: All ako orn

    All ako orn

Allakos — Corporate Update (August 2019) on 6ix